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Summary
LEOPARD syndrome (multiple Lentigines, Electrocar-
diographic conduction abnormalities, Ocular hyper-
telorism, Pulmonic stenosis, Abnormal genitalia, Retar-
dation of growth, and sensorineural Deafness) is a rare
inherited disease. Mutations in the PTPN11 and RAF-1
genes have been reported in patients with LEOPARD
syndrome. 
Although the clinical course is generally favourable, a
number of sudden cardiac deaths have been reported
in association with this syndrome. Patients with hyper-
trophic cardiomyopathy (HCM) have potentially a high-
er risk of developing severe cardiac complications dur-
ing follow-up. Here, we describe a family (mother and
daughter) with clinical and molecular diagnosis of
LEOPARD syndrome 1 and HCM (mild, non obstructive
HCM in the mother; severe, obstructive HCM in the
daughter), and we report the prenatal diagnosis of a se-
vere HCM in a fetus at risk for LEOPARD syndrome.
KEY WORDS: prenatal diagnosis; LEOPARD syndrome; hyper-
trophic cardiomyopathy; natural history.
Introduction
LEOPARD syndrome is an acronym (multiple Lentig-
ines, Electrocardiographic conduction abnormalities,
Ocular hypertelorism, Pulmonic stenosis, Abnormal
genitalia, Retardation of growth, and sensorineural
Deafness) describing an autosomal dominant disease
due to mutations in the RAS-MAPK pathway (1-3). The
PTPN11 gene, encoding the protein tyrosine phos-
phatase SHP-2, causes the disease in 80% of the pa-
tients affected (LEOPARD syndrome type 1) (2). Pandit
et al. recently described RAF-1 mutations in 2 out of six
patients with LEOPARD syndrome without PTPN11 mu-
tations (LEOPARD syndrome type 2) (3). Clinical out-
come is worse in patients with cardiovascular involve-
ment, and a number of fatal events have been reported
in patients affected by hypertrophic cardiomyopathy
(HCM) associated with the syndrome (4, 5). Here, we
describe a family (mother and daughter) with clinical and
molecular diagnosis of LEOPARD syndrome 1 and
HCM, and we report the prenatal diagnosis of HCM in a
fetus at risk for LEOPARD syndrome.
Case Report
The family pedigree is showed in Figure 1. A 32-year-old
woman with LEOPARD syndrome with multiple lentig-
ines, facial dysmorphia, short stature, and mild, non ob-
structive HCM (asymmetric left ventricular hypertrophy,
with maximal wall thickness of 14 mm at the mid-portion
of the posterior interventricular septum, in absence of
outflow tract obstruction) was referred to our Depart-
ment for foetal echocardiography and genetic coun-
selling during her second pregnancy. Her first pregnan-
cy resulted in a daughter (the proband) who was born
with a severe form of obstructive HCM, and pulmonary
valvar and subvalvar stenosis. She had cafè au lait
spots on her trunk, hypertelorism, broad nasal bridge,
pterigium colli, pectus excavatum and short stature. She
was administered with beta blockers (7 mg/kg/day) for
her cardiomyopathy, but she died suddenly at 2 years of
age. Clinical diagnosis of LEOPARD syndrome was
confirmed by genetic analysis showing a mutation in ex-
on 13 of the PTPN11 gene (codon 498), in both mother
and daughter.
During the second pregnancy, prenatal scan at 22
weeks of gestation evidenced fetal growth restriction
(about 3 weeks), and fetal echocardiography showed a
significant hypertrophy of both ventricles (left and right
ventricular wall thickness 9mm and 3 mm, respectively)
(Figure 2). Systolic function was slightly depressed
(ejection fraction measured by biplane Simpson method
was 45%), and diastolic function was abnormal. 
The parents were counselled by a team of physicians
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(gynaecologists, paediatric cardiologists, psychologists,
and geneticists) regarding the clinical manifestations
and outcome of LEOPARD syndrome in general and
HCM associated with this condition in particular and de-
cided to terminate the pregnancy. 
Discussion
HCM is an etiologically heterogeneous condition with in-
trafamilial and interfamilial variability in the clinical man-
ifestations (8). Natural history of early onset HCM is ex-
tremely variable (9, 10). Pedra et al. described prenatal
characteristic and postnatal outcome of 33 foetuses with
hypertrophic cardiomyopathy (11). Two termination of
pregnancy (1 Noonan, 1 sarcomeric hypertrophic car-
diomyopathy) were reported. Of note, one patient with
severe, biventricular hypertrophy survived the perinatal
period, and cardiac hypertrophy resolved by 3 months of
age. 
HCM is the most common defect in patients with LEOP-
ARD syndrome (about 70% of the cases) (6). Long-term
prognosis seems benign in LEOPARD syndrome pa-
tients with only mild cardiac abnormalities (6, 7). On the
other hand, patients with HCM may develop arrhythmias
and other life-threatening complications (6, 7). The phe-
notype (a severe, obstructive left ventricular hypertro-
phy) may represent a risk factor for adverse clinical out-
come (sudden death; as in the present case) in patients
with LEOPARD syndrome and HCM. In addition, the
genotype may represent a potential risk factor of ad-
verse event in selected patients. We have recently re-
ported 2 patients with an early onset obstructive HCM,
associated with a high risk of heart failure and cardiac
events. We showed a specific mutation in exon 13 of the
PTPN11 gene (codon 510) (7). Of note, in the present
report both the mother and her daughter had a mutation
in exon 13 of the PTPN11 gene (codon 498). However,
intrafamilial variability is clear in the present report
(since the mother had a mild form of HCM, while the first
daughter and the foetus showed a severe, early onset
hypertrophic disease), representing a strong limitation to
the potential use of the genotype (i.e. mutations in exon
13) as clinical predictor of malignant events in patients
with HCM and LEOPARD syndrome.   
In conclusion, HCM significantly worsen the prognosis in
LEOPARD syndrome. However, lacking large population
studies on HCM associated to the rare LEOPARD syn-
drome, the clinical and genetic heterogeneity of the dis-
ease warrant particular attention, especially  in prenatal
counselling, which should involve a multidisciplinary and
experienced team (gynecologist, cardiologist, geneti-
cists, and psycologist). 
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Figure 1 - Family Pedigree: an Italian kindred with LEOPARD
syndrome and hypertrophic cardiomyopathy. Proband is indicat-
ed by arrow. Circles indicate females; squares, males; triangle,
sex unknown; open symbols, unaffected individuals; filled sym-
bols, individuals affected (by LEOPARD syndrome); symbols
with slash are deceased individuals; question mark, unknown
clinical status; plus sign, presence of mutation (i.e., PTPN11
mutation); minus sign, absence of mutation. 
Figure 2 - Fetal echocardiography showing hypertrophic car-
diomyopathy. 
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